The Bio Report

The Bio Report

by

The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy. TNF inhibitors, such as Humira and Remicade, have been a great biotech success story. These multi-billion franchises treat a range of autoimmune conditions including rheumatoid arthritis, psoriasis, and Crohn’s disease. Jim Woody, who led Centocor’s development team for Remicade, the first of the TNF-inhibitors, is today in pursuit of new uses for these therapies. Now CEO of 180 Life Sciences, Woody and his team are pushing TNF inhibitors into new indications for inflammatory and fibrotic conditions. We spoke to Woody about the role of TNF in the inflammatory process, the indications his company is pursuing, and why these well-established drugs have gone untapped for these purposes. The Bio Report welcomes DeepDyve as a sponsor. Search 100 million scientific papers with full access to 20 million articles. It’s one-stop, affordable research. Try the enterprise version of the service free for one month. Go to deepdyve.com/podcast and use the code BIOREPORT

Recent Episodes

  • Finding New Uses for TNF Inhibitors

    1 week ago
  • Using AI to Map the Undiscovered World of Bioactive Compounds in Plants

    2 weeks ago
  • Improving the Delivery of Drugs through Thin Film Freezing

    3 weeks ago
  • Using CRISPR to Target RNA Instead of DNA

    1 month ago
  • An Antisense Pioneer Brings Custom Treatments to Patients with Ultra-Rare Conditions

    1 month ago
  • Managing Neurodegenerative Diseases with Better Data to Improve Outcomes

    1 month ago
  • A Small Molecule Cancer Drug That Promotes an Adaptive Immune Response

    2 months ago
  • Sloan-Kettering Spin-Out Harnesses AI to Diagnose Cancer

    2 months ago
  • Bringing Innovation to Cell and Gene Therapy Manufacturing

    2 months ago
  • Tapping Psychedelics for their Anti-Inflammatory Powers

    2 months ago